|
AU5784501A
|
|
Quinoline derivatives as tachykinin NK3 receptor antagonists
|
|
IL128220D0
|
|
Quinoline derivatives and uses thereof
|
|
AU1216299A
|
|
Quinoline derivatives as tachykinin NK3 receptor antagonists
|
|
IL126806D0
|
|
Quinoline derivatives
|
|
HU9903088A3
|
|
Composition comprising mupirocin and chlorhexidine
|
|
WO9602509A1
|
|
Quinoline derivatives as nk3 antagonists
|
|
WO9533487A1
|
|
Injectable formulations containing a desiccant
|
|
ZA9504269B
|
|
Quinoline derivatives
|
|
CA2257662A1
|
|
Quinoline derivatives as tachykinin nk3 receptor antagonists
|
|
ITMI950803A1
|
|
Lactone compounds which are useful for the treatment of osteoporosis
|
|
ITMI950804A1
|
|
Lactone compounds useful for the treatment of osteoporosis
|
|
ITMI950494D0
|
|
New tachykinin receptor antagonising quinoline derivs. - used for treating pulmonary disorders, CNS disorders, skin disorders, neurogenic inflammation, epilepsy and inflammatory pain,etc.
|
|
WO9521843A1
|
|
Azacyclic derivatives
|
|
ITMI950033D0
|
|
Arylalkylene compounds
|
|
ITMI950031D0
|
|
Dibenzoalkylene compounds
|
|
ITMI950032D0
|
|
Aryl alkylene compounds
|
|
CN1145586A
|
|
Taste masked composition containing a drug/polymer complex
|
|
ITMI941462D0
|
|
Heterocyclic-condensate derivatives of morphinoids
|
|
CA2168853A1
|
|
Hydroisoquinoline derivatives
|
|
GB9410986D0
|
|
Imidazopiperidine derivatives
|
